McCulloch Kevin
See Remarks
McCulloch Kevin has filed 9 SEC Form 4 filings (13 transaction rows) across 1 company, with disclosures dating back to 2025. 9 of those filings fall inside the rolling window. Most recent filing: Sep 1, 2026.
On the most recent filing, McCulloch Kevin is listed as See Remarks at Xeris Biopharma Holdings, Inc. Inside the rolling window, McCulloch Kevin reported no open-market purchases and 4 open-market sales totaling $1.1M in XERS. The largest disclosed transaction in the window is a sale of 90,000 XERS shares on Jul 1, 2026, worth $723K.
Companies traded
Other insiders at XERS
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$1.1M
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has McCulloch Kevin made?
McCulloch Kevin has filed 9 SEC Form 4 filings (13 transaction rows) across 1 company since 2025.
Which companies does McCulloch Kevin trade?
McCulloch Kevin has filed SEC Form 4 disclosures for 1 company, including XERS.
When was McCulloch Kevin's most recent SEC Form 4 filing?
McCulloch Kevin's most recent SEC Form 4 filing on Tracefour is dated Sep 1, 2026.
What is McCulloch Kevin's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, McCulloch Kevin is listed as See Remarks.
What is McCulloch Kevin's total buy and sell value in the current window?
Inside the rolling retention window, McCulloch Kevin bought $0 and sold $1.1M based on SEC Form 4 filings.
What was McCulloch Kevin's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 90,000 XERS shares on 2026-07-01, worth $723K, per SEC Form 4 filings.